Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $497.57M
• Dividend Yield: N/A
• Average Volume (3M): 1.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 13.17%
• EPS Growth: 64.50%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 379,822,270
• 10 Day Avg. Volume: 1,149,872
• 30 Day Avg. Volume: 1,416,869
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 1.46
• Enterprise Value/Gross Profit: 3.11
• Enterprise Value/Ebitda: -2.12
• 1Y Price Target: $1.53
• Price Target Upside: 16.79% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 56 Neutral
• Price Target: $1.50 ▲(14.50% Upside)

Standard BioTools' overall stock score is primarily influenced by its financial challenges and valuation concerns, which are offset by positive corporate events and strategic initiatives. The company's efforts to streamline operations and improve cash reserves are promising, but profitability remains a key concern.

Positive Factors

Financial Performance

LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.

Management Initiatives

Cost and operational initiatives continue to bear fruit with an adjusted operating loss improving by about 45% year over year despite a tough backdrop.

Operational Improvement

Solid operational expense controls showcase operational improvement despite a gross margin miss.

Negative Factors

Market Conditions

The '25 revenue was guided to $165-175M, disappointing versus consensus due to market headwinds like capex budgets and NIH uncertainty.

Revenue Guidance

LAB posted its preannounced 4Q24 with disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M.

Spending Environment

With a tepid spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, a downgrade to Sector Weight was issued.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools (LAB) is a biotechnology company that specializes in developing innovative tools and technologies for genomic analysis. The company operates primarily in the life sciences sector, providing products and services designed for researchers in genomics, proteomics, and cellular analysis. Standard BioTools' core offerings include advanced sequencing technologies, microfluidic devices, and software solutions that facilitate high-throughput data generation and analysis, empowering scientists to make breakthroughs in personalized medicine and biological research.

How the Company Makes Money

Standard BioTools generates revenue through multiple key streams, primarily by selling its proprietary laboratory instruments, consumables, and software solutions to research institutions, pharmaceutical companies, and clinical laboratories. The company also benefits from ongoing service contracts and maintenance agreements for its equipment, which provide a steady revenue flow. Additionally, Standard BioTools engages in strategic partnerships with academic institutions and industry players, allowing for collaborative research efforts that can lead to innovative product development and expanded market reach. These partnerships often include licensing agreements, which can further enhance the company's revenue potential.

Standard BioTools Financial Statement Overview

Summary

Standard BioTools faces significant financial challenges, with persistent losses impacting profitability and cash flow. While the balance sheet is moderately stable due to a strong equity position, high leverage and negative cash flows pose risks. The company needs to address operational inefficiencies and improve revenue growth to achieve financial stability.

Income Statement

The company's income statement shows significant challenges with profitability. The TTM data reveals a negative net profit margin and declining revenue, indicating persistent losses. The gross profit margin is relatively stable but overshadowed by high operating losses, reflected in negative EBIT and EBITDA margins. Revenue growth is inconsistent, with recent periods showing a decline. These factors suggest difficulties in scaling operations profitably.

Balance Sheet

The balance sheet reflects a strong equity position with a positive equity ratio, but the company is highly leveraged, indicated by a significant debt-to-equity ratio. The return on equity is negative due to consistent net losses. However, cash reserves are healthy, partially offsetting the risks from high leverage. The overall balance sheet stability is moderate, with some financial risks due to the dependency on debt.

Cash Flow

The cash flow statement shows negative operating and free cash flows, indicating cash burn and potential liquidity issues. However, there is a notable improvement in cash flow from financing activities, bolstering cash reserves. The company struggles with converting revenue to cash, as seen in low ratios of cash flow to net income. The trajectory of cash flows suggests efficiency improvements are necessary to achieve sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	169.69M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	79.81M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-116.89M	-118.14M	-54.46M	-173.57M	-43.77M	-32.59M
Net Income	-132.76M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	579.60M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	258.06M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	31.53M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	125.00M	140.62M	159.87M	471.78M	180.62M	185.71M
Stockholders Equity	454.60M	471.72M	163.20M	229.79M	94.60M	139.05M
Cash Flow
Free Cash Flow	-123.89M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-111.26M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	59.72M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-82.93M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.31 is below the 20-day moving average (MA) of 1.33, above the 50-day MA of 1.24, and below the 200-day MA of 1.41, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 45.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	60 Neutral	$643.10M	―	-4.54%	―	4.31%	69.57%
LAB	56 Neutral	$497.57M	―	-22.40%	―	13.17%	64.50%
CSTL	56 Neutral	$561.02M	30.59	-2.15%	―	20.40%	-165.41%
Sector *	51 Neutral	$7.42B	-0.36	-44.95%	2.27%	22.89%	-2.16%
MYGN	51 Neutral	$561.06M	―	-70.03%	―	3.83%	-137.31%
PSNL	49 Neutral	$405.25M	―	-60.26%	―	0.36%	22.13%
OPK	44 Neutral	$1.05B	―	-13.16%	―	-7.31%	29.84%

Standard BioTools Corporate Events

Standard BioTools Announces SomaLogic Sale to Illumina

Standard BioTools reported its financial results for the second quarter of 2025, highlighting a total revenue of $42 million, with $21.8 million from continuing operations. The company announced the strategic sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026, which will significantly bolster its cash reserves to at least $550 million. This move is part of a broader strategy to streamline operations and focus on profitability by 2026, despite challenges such as reduced U.S. academic spending and global capital constraints. The company is pausing its earnings calls temporarily to focus on operational adjustments.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Approves Stock Awards for Executives

On July 29, 2025, Standard BioTools Inc. announced that its Board of Directors approved restricted stock unit retention awards for its President & CEO, Michael Egholm, and CFO, Alex Kim, effective August 1, 2025. These awards, part of the company’s 2011 Equity Incentive Plan, aim to retain key executives by offering significant stock incentives contingent on continued employment. Additionally, the Human Capital Committee approved an increase in Mr. Kim’s annual performance bonus target to 80% of his base salary, effective January 1, 2025, highlighting the company’s commitment to rewarding its leadership.

The most recent analyst rating on (LAB) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Sells Subsidiaries to Illumina

On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Approves Equity Plan Amendment at Meeting

Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.

The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.